Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of acalabrutinib plus venetoclax and rituximab (AVR) in patients with mantle cell lymphoma (MCL). Prof. Wang then goes on to discuss the importance of chemotherapy-free regimens and where these may fit in the MCL treatment landscape, and concludes by commenting on the growing role of targeted immunotherapy combinations. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
